Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1674
    +0.0017 (+0.15%)
     

  • GBP/USD

    1.2480
    -0.0031 (-0.25%)
     

  • Bitcoin GBP

    50,869.86
    -403.89 (-0.79%)
     

  • CMC Crypto 200

    1,321.87
    -74.66 (-5.35%)
     

  • S&P 500

    5,102.55
    +54.13 (+1.07%)
     

  • DOW

    38,252.96
    +167.16 (+0.44%)
     

  • CRUDE OIL

    84.07
    +0.50 (+0.60%)
     

  • GOLD FUTURES

    2,348.70
    +6.20 (+0.26%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

U.S. says Shire subsidiaries to pay $350 mln to settle false claims act allegations

Reuters - UK Focus

WASHINGTON, Jan 11 (Reuters) - Shire PLC (Xetra: S7E.DE - news) subsidiaries will pay $350 million to settle U.S. federal and state False Claims Act (Stuttgart: 0LW.SG - news) allegations related to unlawful methods to push "Dermagraft," a treatment for diabetic foot ulcers, the U.S. Justice Department said in a statement on Wednesday.

"The settlement resolves allegations that Dermagraft salespersons unlawfully induced clinics and physicians with lavish dinners, drinks, entertainment and travel; medical equipment and supplies; unwarranted payments for purported speaking engagements and bogus case studies; and cash, credits and rebates, to induce the use of Dermagraft," it said. (Reporting by Washington Newsroom; Editing by Chizu Nomiyama)